Ubrogepant

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 199 publications

Focus on migraine prodrome: what should clinicians know?

Focus on migraine prodrome: what should clinicians know?

Journal: Current opinion in neurology
Published: April 09, 2026

Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.

Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.

Journal: Pain physician
Published: February 02, 2026

Migrainous Thoracalgia in a Patient with Chronic Migraine and Coronary Vasospasm: A Case Report.

Migrainous Thoracalgia in a Patient with Chronic Migraine and Coronary Vasospasm: A Case Report.

Journal: International medical case reports journal
Published: January 30, 2026

Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open-Label Trial.

Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open-Label Trial.

Journal: Clinical and translational science
Published: January 02, 2026

Population Pharmacokinetics and Exposure-Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1-3 Studies.

Population Pharmacokinetics and Exposure-Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1-3 Studies.

Journal: Journal of clinical pharmacology
Published: December 16, 2025

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends.

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends.

Journal: Headache
Published: December 13, 2025

Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists: evidence from the FDA Adverse Event Reporting System.

Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists: evidence from the FDA Adverse Event Reporting System.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: December 09, 2025

Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care.

Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care.

Journal: The American journal of managed care
Published: November 25, 2025

Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

Journal: Pain management
Published: November 19, 2025

Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists.

Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists.

Journal: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Published: October 22, 2025

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.

Journal: Headache
Published: October 13, 2025

Gepants: targeting the CGRP pathway for migraine relief.

Gepants: targeting the CGRP pathway for migraine relief.

Journal: Frontiers in pharmacology
Published: September 18, 2025
Showing 1-12 of 199

Last Updated: 06/30/2026